ZABOFLOXACIN HYDROCHLORIDE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H20FN5O4.ClH
Molecular Weight	437.853
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CO\N=C1/CN(CC12CNC2)C3=NC4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=IFPBSRFVNPCZMK-MHVDTSALSA-N

InChI=1S/C19H20FN5O4.ClH/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17;/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28);1H/b23-14+;

HIDE SMILES / InChI

Molecular Formula	C19H20FN5O4
Molecular Weight	401.3916
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT01658020 | https://clinicaltrials.gov/ct2/show/NCT01081964 | https://www.ncbi.nlm.nih.gov/pubmed/20403681

Zabofloxacin (also known as DW-224a), a fluoroquinolone antibiotic agent, is a dual inhibitor of both DNA gyrase and topoisomerase IV of Streptococcus pneumonia. Zabofloxacin successfully has completed phase III clinical trial in patients with acute bacterial exacerbation of the chronic obstructive pulmonary disease. In addition, in May 2012, IASO terminated phase II trial of oral zabofloxacin capsules in patients with moderate-to-severe community-acquired pneumonia due to financial considerations.

Originator

Approval Year

PubMed

Title	Date	PubMed
Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent.	2004 Nov	15573468
Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.	2008 Sep	18620833
DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.	2010 Jul	20403681
New treatment options for lower respiratory tract infections.	2017 Sep	28762839

Patents

Sample Use Guides

In Vivo Use Guide

Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:24:54 GMT 2025` Edited by `admin` on `Mon Mar 31 22:24:54 GMT 2025`
Record UNII	O889MR47PQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZABOFLOXACIN HYDROCHLORIDE

Common Name

English

DW-224A

Preferred Name

English

1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-7-(8-(METHOXYIMINO)-2,6-DIAZASPIRO(3.4)OCT-6-YL)-4-OXO-, MONOHYDROCHLORIDE

Systematic Name

English

ZABOFLOXACIN MONOHYDROCHLORIDE

Common Name

English

Zabofloxacin hydrochloride [WHO-DD]

Common Name

English

1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-7-(8-(METHOXYIMINO)-2,6-DIAZASPIRO(3.4)OCT-6-YL)-4-OXO-, HYDROCHLORIDE (1:1)

Systematic Name

English

Code System Code Type Description

SMS_ID

100000182644